Table 2.
Summary of included studies
| Qualitative studies | |||||
|---|---|---|---|---|---|
| Author (year) | Country | Main topic | Design/method | Participants (n) | Cancer field |
| Abe (2017) [24] | USA | Genomics-informed treatment decisions for radiation therapy | Semi-structured stakeholder meetings | Patients, surgeons, oncologists, industry representatives, biomedical informatics. N = 22 | Prostate cancer |
| Bijlsma (2018) [25] | The Netherlands | Unsolicited genetic information obtained using NGS | Individual interviews | Patients n = 24 | Cancer |
| Bombard (2014) [26] | Canada | Gene expression profiling | Individual interviews, focus group discussion |
Oncologists, n = 14 patients, n = 28 |
Breast cancer |
| Bombard (2015) [27] | Canada | Gene expression profiling | Individuals interviews | Oncologists n = 14 | Breast cancer |
| Costa (2021) [28] | Canada | Prognostic-based genomic testing | Focus group discussions | Patients, n = 26 | Lymphoid Cancers |
| Dodson (2017) [29] | USA | Pharmacogenomics | Open-ended survey | Oncology nurses, n = 28 | Cancer |
| Hamilton (2021) [30] | USA | Precision oncology | Focus group discussions | Oncology clinicians, n = 68 | Breast, melanoma and thoracic cancer |
| Hamilton (2017) [31] | USA | Secondary germline findings from tumor genomic profiling | Individual interviews | Patients with advanced cancer, n = 40 | Breast, bladder, colorectal, or lung cancer |
| Harris (2013) [32] | USA | Kirsten ras tumor mutation testing (KRAS) | Individual interviews | Oncologists, n = 34 | Colorectal cancer |
| Kerr (2019) [33] | UK | Molecular cancer diagnosis/treatment | Individual interviews | Practitioners n = 25 | Cancer |
| Mamzer (2017)a [34] | France | Translational oncology research | Case study |
Patient and expert committee members, n = not specified |
Cancer |
| McCradden (2020) [35] | Canada | AI in health care research | Individual interviews | Patients, caregivers, and health-care providers, n = 30 | Meningioma |
| Perry (2017) [36] | Germany | "Personalized" treatment research (e.g. biomarkers for stratification) | Individual interviews | Patients, n = 40 | Colorectal cancer |
| Pellegrini (2011) [37] | France | Tumor gene expression analysis | Individual interviews | Patients, n = 37 | Breast cancer |
| Pichler (2020) [38] | Germany | Molecular diagnosis | Individual interviews | Patients, n = 30 | Cancer, advanced stage |
| Rattay (2018) [39] | UK | Predictive radiogenomics testing for breast radiation toxicity | Individual interviews | Patients, n = 21 | Breast cancer |
| Rohrmoser (2019) [40] | Germany | Molecular diagnostics | Individual interviews | Patients, n = 30 | Cancer, advanced stage |
| Steltzer (2020) [41] | Austria | Personalized medicine | Individual interviews |
Patients n = 2 Health care professionals, n = 14 |
Cancer |
| Therond (2020) [42] | UK | BRCA genetic testing | Observation and individual interviews | Patients, n = 25 | Breast, ovarian |
| Wright (2019) [43] | UK | BRCA 1 & 2 testing | Individual interviews and team meetings |
Clinicians n = 19, teams |
Breast cancer |
| Mixed-methods | |||||
| Best (2020) [44] | Australia | Somatic molecular profiling (MP) test results | Survey and individual interviews | Patients survey n = 1299, interview n = 20 | Advanced cancers |
| Quantitative methods | |||||
| Issa (2013) [45] | USA | Novel personalized medicine genomic diagnostics | Discrete Choice Experiment survey | Patients, n = 300 | breast and colorectal |
| Soellner (2021) [46] | USA | AI for diagnostics | Survey | Public, n = 452 | Skin cancer |
| Yang (2019) [47] | China | AI in medicine | Survey | Patients, n = 527 | Cancer |
| Theoretical, opinion pieces | |||||
| Aminololama-Shakeri (2019) [48] | USA | AI in breast imaging radiology | Opinion paper | Breast | |
| Ansmann (2018) [49] | Germany | Precision medicine | Commentary | Cancer | |
| Bunnik (2021) [50] | The Netherlands | Genomic sequencing | Perspective | Cancer | |
| Carter (2020) [51] | Australia | AI systems | Theoretical review | Breast cancer | |
| Korngiebel (2017) [52] | USA | Pharmacogenomic tests and tests for inherited cancer risk | Review/theoretical | Cancer | |
| Marchiano (2018) [53] | USA | Precision oncology | Communication | Cancer | |
| McFarland (2017) [54] | USA | Precision medicine oncology and targeted therapies | Editorial | Cancer | |
| McFarland (2017) [55] | USA | Precision medicine oncology | Editorial | Cancer | |
| McGrath (2021) [56] | USA | Genetic and genomic testing | Perspective | Cancer | |
| Stoeklé (2018) [57] | France | Precision medicine, Molecular tumor board (MTB) | Opinion paper | Cancer | |
| Triberti (2020) [58] | Italy | AI health decision making | Perspective | Cancer | |
aThe study by Mamzer et al. (2017) is a description of the involvement of patient representatives and to establish a long-term partnership integrating patient’s expectations. No formal qualitative analysis was performed. It was, therefore, not included in the quality assessment